2-(4-cyclohexylbutyl)isoindoline-1,3-dione | 906100-43-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-(4-cyclohexylbutyl)isoindoline-1,3-dione
• 英文别名: N-[4-cyclohexylbut-1-yl]phthalimide；2-(4-Cyclohexylbutyl)isoindole-1,3-dione
• CAS: 906100-43-4
• 化学式: C₁₈H₂₃NO₂
• 分子量: 285.386
• InChiKey: PSPSKTWHDZBUHS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-cyclohexylbutyl)isoindoline-1,3-dione 在 一水合肼 、 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 3.0h， 生成 4-cyclohexyl-1-butanamine hydrochloride
  参考文献：
  名称：

  [EN] BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS
  [FR] DÉRIVÉS DE BENZOXAZOLONE EN TANT QU'INHIBITEURS DE LA CÉRAMIDASE ACIDE, ET LEUR UTILISATION COMME MÉDICAMENTS

  摘要：

  本发明涉及苯并噁唑酮衍生物作为酸酶抑制剂，含有这些抑制剂的药物组合物以及用于抑制酸酶治疗临床相关的调节神经酰胺水平的疾病的方法。该发明还提供苯并噁唑酮衍生物作为药物在治疗癌症、炎症、疼痛、炎症性疼痛或肺部疾病中的用途。

  公开号：

  WO2015173168A1
• 作为产物：
  描述：

  邻苯二甲酸亚胺 、 4-环己基-1-丁醇 在 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 15.0h， 生成 2-(4-cyclohexylbutyl)isoindoline-1,3-dione
  参考文献：
  名称：

  [EN] BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS
  [FR] DÉRIVÉS DE BENZOXAZOLONE EN TANT QU'INHIBITEURS DE LA CÉRAMIDASE ACIDE, ET LEUR UTILISATION COMME MÉDICAMENTS

  摘要：

  本发明涉及苯并噁唑酮衍生物作为酸酶抑制剂，含有这些抑制剂的药物组合物以及用于抑制酸酶治疗临床相关的调节神经酰胺水平的疾病的方法。该发明还提供苯并噁唑酮衍生物作为药物在治疗癌症、炎症、疼痛、炎症性疼痛或肺部疾病中的用途。

  公开号：

  WO2015173168A1

文献信息

• Transition metal complexes of N-heterocyclic carbenes, method of preparation and use in transition metal catalyzed organic transformations
  申请人：Organ G. Michael

  公开号：US20070073055A1

  公开（公告）日：2007-03-29

  The present invention relates to catalysts of transition metal complexes of N-heterocyclic carbenes, their methods of preparation and their use in chemical synthesis. The synthesis, ease-of-use, and activity of the compounds of the present invention are substantial improvements over in situ catalyst generation. Further, the transition metal complexes of N-heterocyclic carbenes of the present invention may be used as precatalysts in metal-catalyzed cross-coupling reactions.

  本发明涉及N-杂环卡宾的过渡金属配合物催化剂，其制备方法以及它们在化学合成中的应用。本发明化合物的合成、易用性和活性明显优于原位催化剂生成。此外，本发明的N-杂环卡宾的过渡金属配合物可以作为金属催化的交叉偶联反应中的预催化剂。
• Free-radical anti-Markovnikov hydroalkylation of unactivated alkenes with simple alkanes
  作者：Yunfei Tian、Anbo Ling、Ren Fang、Ren Xiang Tan、Zhong-Quan Liu

  DOI：10.1039/c8gc01394b

  日期：——

  A Cu(II)-mediated radical anti-Markovnikov hydroalkylation of unactivated alkenes with simple alkanes via selective C(sp3)–H bond cleavage was achieved. This reaction features high site-selectivity diverse functional group tolerance, and scalability.

  通过选择性的C（sp 3）–H键裂解，实现了Cu（II）介导的未活化烯烃与简单烷烃的自由基抗马尔科夫尼科夫加氢烷基化反应。该反应具有高位点选择性，多样化的官能团耐受性和可扩展性。
• Anti-Markovnikov Hydroalkylation of Allylic Amine Derivatives via a Palladium-Catalyzed Reductive Cross-Coupling Reaction
  作者：Ryan J. DeLuca、Matthew S. Sigman

  DOI：10.1021/ja204080s

  日期：2011.8.3

  Palladium-catalyzed hydroalkylation of allylic amine derivatives by alkylzinc reagents is reported. This reductive cross-coupling reaction yields anti-Markovnikov products using a variety of allylic amine protecting groups. Preliminary mechanistic studies suggest that a reversible β-hydride elimination/hydride insertion process furnishes the primary Pd-alkyl intermediate, which then undergoes transmetalation

  报道了烷基锌试剂在钯催化下烯丙基胺衍生物的加氢烷基化。这种还原性交叉偶联反应使用各种烯丙胺保护基团产生抗马尔科夫尼科夫产物。初步机理研究表明，可逆的 β-氢化物消除/氢化物插入过程提供初级 Pd-烷基中间体，然后进行金属转移，然后还原消除以形成新的 sp(3)-sp(3) 碳-碳键。
• N-Alkenyl and cycloalkyl carbamates as dual acting histamine H3 and H4 receptor ligands
  作者：Małgorzata Więcek、Tim Kottke、Xavier Ligneau、Walter Schunack、Roland Seifert、Holger Stark、Jadwiga Handzlik、Katarzyna Kieć-Kononowicz

  DOI：10.1016/j.bmc.2011.03.046

  日期：2011.5

  Previous studies have shown that several imidazole derivatives posses affinity to histamine H-3 and H-4 receptors. Continuing our study on structural requirements responsible for affinity and selectivity for H-3/H-4 receptor subtypes, two series of 3-(1H-imidazol-4-yl) propyl carbamates were prepared: a series of unsaturated alkyl derivatives (1-9) and a series possessing a cycloalkyl group different distances to the carbamate moiety (10-13). The compounds were tested for their affinities at the human histamine H3 receptor, stably expressed in CHO-K1 cells. Compounds 1, 2, 5-7, 10-13 were investigated for their affinities at the human histamine H-4 receptor co-expressed with G alpha(i2) and G beta(1)gamma(2) subunits in Sf9 cells. To expand the pharmacological profile, compounds were further tested for their H3 receptor antagonist activity on guinea pig ileum and in vivo after oral administration to mice. All tested compounds exhibited good affinity for the human histamine H-3 receptor with K-i values in the range from 14 to 194 nM. All compounds were active in vivo after peroral administration (p.o.) to Swiss mice, thus demonstrating their ability to cross the blood-brain barrier. The most potent H-3 receptor ligand of these series was compound 5, 3-(1H-imidazol-4-yl) propyl pent-4-enylcarbamate with the highest affinity (K-i = 14 nM). Additionally, compound 3 showed remarkable central nervous system (CNS) H3R activity, increasing the N-tau-methylhistamine levels in mice with an ED50 value of 0.55 mg/kg, p.o. evidencing therefore, a twofold increase of inverse agonist/antagonist potency compared to the reference inverse agonist/antagonist thioperamide. In this study, the imidazole propyloxy carbamate moiety was kept constant. The different lipophilic moieties connected to the carbamate functionality in the eastern part of the molecule had a range of influences on the human H-4 receptor affinity (154-1326 nM). (C) 2011 Elsevier Ltd. All rights reserved.
• US7250510B2
  申请人：——

  公开号：US7250510B2

  公开（公告）日：2007-07-31